Bleeding patterns associated with oral contraceptive use: a review of the literature

Contraception

Volumn 76, Issue 3, 2007, Pages 182-189

  Bachmann, Gloria ^a   Korner, Paul ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Bleeding; Oral contraception; Reference periods

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; ETYNODIOL DIACETATE; GESTAGEN; LEVONORGESTREL; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO;

AMENORRHEA; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; HUMAN; INCIDENCE; MEDICAL PARAMETERS; MENSTRUAL IRREGULARITY; MENSTRUATION; ORAL CONTRACEPTION; REFERENCE VALUE; REVIEW; SPOTTING; STANDARDIZATION; STATISTICS; SYSTEMATIC REVIEW; VAGINA BLEEDING; WORLD HEALTH ORGANIZATION;

CONTRACEPTIVES, ORAL; FEMALE; HUMANS; UTERINE HEMORRHAGE;

EID: 34547920713     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.05.081     Document Type: Review

References (26)

1. Mishell Jr. D.R., Guillebaud J., Westhoff C., et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 75 (2007) 4-10
2. Belsey E.M., Machin D., and d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World health organization special programme of research, development and research training in human reproduction. Contraception 34 (1986) 253-260
3. Rodriguez G., Faundes-Latham A., and Atkinson L.E. An approach to the analysis of menstrual patterns in the critical evaluation of contraceptives. Stud Fam Plann 7 (1976) 42-51
4. Belsey E.M., and Pinol A.P. Menstrual bleeding patterns in untreated women. Task force on long-acting systemic agents for fertility regulation. Contraception 55 (1997) 57-65
5. Belsey E.M., and Peregoudov S. Determinants of menstrual bleeding patterns among women using natural and hormonal methods of contraception: I. Regional variations. Contraception 38 (1988) 227-242
6. Belsey E.M. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception 38 (1988) 207-225
7. Belsey E.M. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 38 (1988) 181-206
8. Foidart J.M., Sulak P.J., Schellschmidt I., and Zimmermann D. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 73 (2006) 34-40
9. Bachmann G., Sulak P.J., Sampson-Landers C., Benda N., and Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone. Contraception 70 (2004) 191-198
10. Westhoff C., Morroni C., Kerns J., and Murphy P.A. Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial. Fertil Steril 79 (2003) 22-29
11. Kaunitz A.M. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. Contraception 61 (2000) 295-302
12. Schwarz B.E., Pierce C., Walden C.E., and Knopp R.H. Reference period analysis of vaginal bleeding with triphasic oral contraceptive agents containing norethindrone or levonorgestrel: a comparison study. Int J Fertil 37 (1992) 176-182
13. Anonymous, and The Mircette Study Group. An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. Am J Obstet Gynecol 179 (1998) S2-S8
14. Shroff N.E., Pearce M.Y., Stratford M.E., and Wilkinson P.D. Clinical experience with ethynodiol diacetate 0.5 mg daily as an oral contraceptive. Contraception 35 (1987) 121-134
15. Killick S.R., Fitzgerald C., and Davis A. Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 179 (1998) S18-S24
16. Rice C., Killick S., Hickling D., and Coelingh Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod 11 (1996) 737-740
17. Kaunitz A.M., Garceau R.J., and Cromie M.A. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group. Contraception 60 (1999) 179-187
18. Miller L., and Notter K.M. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 98 (2001) 771-778
19. Miller L., and Hughes J.P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 101 (2003) 653-661
20. Westhoff C., Osborne L.M., Schafer J.E., and Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstet Gynecol 106 (2005) 89-96
21. Anderson F.D., Gibbons W., and Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 195 (2006) 92-96
22. Anderson F.D., Gibbons W., and Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 73 (2006) 229-234
23. Anonymous, and Collaborative Study Group on the Desogestrel-Containing Progestogen-Only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 3 (1998) 169-178
24. Krettek J.E., Arkin S.I., Chaisilwattana P., and Monif G.R. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet Gynecol 81 (1993) 728-731
25. Rosenberg M.J., Waugh M.S., and Higgins J.E. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. Contraception 53 (1996) 85-90
26. Mishell Jr. D.R., Guillebaud J., Westhoff C., et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 75 (2007) 11-15